1.1.1.B52	A158A/N162P	96.8% enantiomeric excess for (R)-3-quinuclidinol production, 82% conversion	738052	
1.1.1.B52	A158D/N162G	96.5% enantiomeric excess for (R)-3-quinuclidinol production, 87% conversion	738052	
1.1.1.B52	A158D/N162Q	95.8% enantiomeric excess for (R)-3-quinuclidinol production, 79% conversion	738052	
1.1.1.B52	A158H/N162G/K202Q/L224W	mutations increase the enantiomeric excess for (R)-3-quinuclidinol production from 84.3% (wild-type) to 99% and concomitantly to enhance conversion by 43.5%	738052	
1.1.1.B52	A158H/N162P	98.1% enantiomeric excess for (R)-3-quinuclidinol production, 95% conversion	738052	
1.1.1.B52	A158K/N162M	97.6% enantiomeric excess for (R)-3-quinuclidinol production, 98% conversion	738052	
1.1.1.B52	D40A	no activity	729146	
1.1.1.B52	D40A	site-directed mutagenesis, inactive mutant	741816	
1.1.1.B52	E197A	no activity	729146	
1.1.1.B52	E197A	site-directed mutagenesis, inactive mutant	741816